Respiratory Syncytial Virus antibody

100% Secure

Goat anti Respiratory Syncytial Virus:Biotin

Goat anti Respiratory Syncytial Virus:HRP

Goat anti Respiratory Syncytial Virus

Product Type
Polyclonal Antibody
Isotype
Polyclonal IgG
Product CodeApplicationsDatasheetMSDSPack SizeList PriceQuantity
7950-0104 C E FN 1 ml
7950-0304 C E IF P 1 ml
7950-0004 C E FN* IF 1 ml
Goat anti respiratory syncitial virus polyclonal antibody recognizes respiratory syncytial virus (RSV) a negative-sense, single-stranded RNA virus and member of the Paramyxoviridae family. RSV causes respiratory tract infections in patients of all ages, but particularly affects infants and the immunosuppressed.

RSV encodes three envelope glycoproteins, a small hydrophobic (SH) protein of unknown function, a glycoprotein (G) known as the attachment protein, and a fusion (F) protein. The F protein directs fusion of viral and cellular membranes, resulting in viral penetration, and can lead to the formation of syncytia.

The F protein is thought to be the principal antigen responsible for inducing an immune response.

Goat anti respiratory syncitial virus does not react with Parainfluenza 1-3, Influenza A and B, Adenovirus or uninfected HEp-2 or WI-38 cells. Goat anti respiratory syncitial virus polyclonal antibody is neutralizing and reacts well with bovine isolates.

Product Details

Target Species
Viral
Product Form
Purified IgG conjugated to Biotin - liquid
Product Form
Purified IgG conjugated to Horseradish Peroxidase (HRP) - liquid
Product Form
Purified IgG - liquid
Buffer Solution
Phosphate buffered saline
Buffer Solution
Phosphate buffered saline
Buffer Solution
Phosphate buffered saline
Preservative Stabilisers
0.1% Sodium Azide (NaN3)
Preservative Stabilisers
0.002%Thiomersal
1%Bovine Serum Albumin
Preservative Stabilisers
0.1% Sodium Azide (NaN3)
Immunogen
Human RSV isolate.
Approx. Protein Concentrations
IgG concentration 4.0 mg/ml
Approx. Protein Concentrations
1.0 mg/ml
Approx. Protein Concentrations
IgG concentration 4.0 mg/ml

Storage Information

Storage
Store at +4oC or at -20oC if preferred.
Storage in frost-free freezers is not recommended.
This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.
Storage
Store at +4oC or at -20oC if preferred.
Storage in frost-free freezers is not recommended.
This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.
Storage
Store at +4oC or at -20oC if preferred.
Storage in frost-free freezers is not recommended.
This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.
Shelf Life
18 months from date of despatch.
Shelf Life
18 months from date of despatch.
Shelf Life
18 months from date of despatch.

More Information

Regulatory
For research purposes only

Applications of Respiratory Syncytial Virus antibody

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit the antibody protocols page.
Application Name Verified Min Dilution Max Dilution
ELISA
Functional Assays
Immunohistology - Frozen
ELISA 1/200 1/1000
Immunofluorescence 1/20 1/200
Immunohistology - Frozen 1/20 1/200
Immunohistology - Paraffin
ELISA
Functional Assays 1
Immunofluorescence
Immunohistology - Frozen
  1. 1This product contains sodium azide, removal by dialysis is recommended prior to use in functional assays. Bio-Rad recommend the use of EQU003 for this purpose.
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using the appropriate negative/positive controls.
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using the appropriate negative/positive controls.

Secondary Antibodies Available

Description Product Code Pack Size Applications List Price Quantity
Rabbit anti Goat IgG (Fc):FITC STAR122F 1 mg F
Rabbit anti Goat IgG (Fc):HRP STAR122P 1 mg C E WB

Useful Reagents Available

Description Product Code Pack Size Applications List Price Quantity
AbGUARD® HRP Stabilizer Plus BUF052A 100 ml C E P WB
AbGUARD® HRP Stabilizer Plus BUF052B 500 ml C E P WB
AbGUARD® HRP Stabilizer Plus BUF052C 1000 ml C E P WB
TMB Signal+ BUF054A 100 ml E
TMB Core BUF056A 100 ml E
TMB Core+ BUF062A 100 ml E

Application Based External Images

Immunofluorescence

Immunohistology - Frozen

Product Specific References

References for Respiratory Syncytial Virus antibody

  1. Culley, F.J. et al. (2006) Role of CCL5 (RANTES) in viral lung disease.
    J Virol. 80: 8151-7.
  2. Numata, M. et al. (2010) Pulmonary surfactant phosphatidylglycerol inhibits respiratory syncytial virus-induced inflammation and infection.
    Proc Natl Acad Sci U S A. 107: 320-5.
  3. Roux, X. et al. (2008) Sub-nucleocapsid nanoparticles: a nasal vaccine against respiratory syncytial virus.
    PLoS One. 3: e1766.
  4. Olszewska, W. et al. (2011) Antiviral and lung protective activity of a novel RSV fusion inhibitor in a mouse model.
    Eur Respir J. 38: 401-8.
  5. Fonceca AM et al. (2012) Primary airway epithelial cultures from children are highly permissive to respiratory syncytial virus infection.
    Thorax. 67 (1): 42-8.
  6. Ryzhakov, G. et al. (2011) IL-17 Boosts Proinflammatory Outcome of Antiviral Response in Human Cells.
    J Immunol. 187: 5357-62.
  7. Fricke J et al. (2013) p38 and OGT sequestration into viral inclusion bodies in cells infected with human respiratory syncytial virus suppresses MK2 activities and stress granule assembly.
    J Virol. 87 (3): 1333-47.
  8. Kipper, S. et al. (2015) New host factors important for respiratory syncytial virus (RSV) replication revealed by a novel microfluidics screen for interactors of matrix (M) protein.
    Mol Cell Proteomics. 14 (3): 532-43.
  9. Russell, R.F. et al. (2015) Partial Attenuation of Respiratory Syncytial Virus with a Deletion of a Small Hydrophobic Gene Is Associated with Elevated Interleukin-1β Responses.
    J Virol. 89 (17): 8974-81.
  10. Currie, S.M. et al. (2016) Cathelicidins Have Direct Antiviral Activity against Respiratory Syncytial Virus In Vitro and Protective Function In Vivo in Mice and Humans.
    J Immunol. 196 (6): 2699-710.
  11. Kinnear, E. et al. (2017) Airway T cells protect against RSV infection in the absence of antibody.
    Mucosal Immunol. May 24. [Epub ahead of print]
  12. Bajimaya, S. et al. (2017) Cholesterol is required for stability and infectivity of influenza A and respiratory syncytial viruses.
    Virology. 510: 234-41.